Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
Eur J Hosp Pharm
; 30(e1): e106-e108, 2023 03.
Article
en En
| MEDLINE
| ID: mdl-33990390
ABSTRACT
OBJECTIVE:
Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets.METHODS:
Blood samples were drawn from patients with COVID-19 who were receiving crushed LPV/RTV 400/100 mg tablets twice daily.RESULTS:
Plasma concentrations for 11 patients with COVID-19 (eight men, mean age 62.6 years) were included. The measured plasma concentrations of LPV were substantially higher than reported for patients with HIV.CONCLUSIONS:
There is adequate exposure from crushed LPV/RTV tablets, but because of limited experience, therapeutic drug monitoring is still advised.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ritonavir
/
COVID-19
Límite:
Adult
/
Child
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2023
Tipo del documento:
Article